Alia Therapeutics is developing next-generation gene-editing medicines to cure rare genetic diseases.
Alia Therapeutics has raised $4.8M in total funding. The most recent round was Seed. The last funding was announced in April 2023.
Alia Therapeutics's investors include Sofinnova Partners, Indaco Venture Partners, BiovelocITA, Trentino Invest Srl.
Alia Therapeutics is headquartered in Trento, Italy.
Alia Therapeutics is developing next-generation gene-editing medicines to cure rare genetic diseases.
Alia Therapeutics is at the Seed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Alia Therapeutics — Funding & Investors." VCBacked, April 17, 2023, https://www.vcbacked.co/company/alia-therapeutics. Accessed September 30, 2026.
VCBacked. (2023). Alia Therapeutics — Funding & Investors. Retrieved September 30, 2026, from https://www.vcbacked.co/company/alia-therapeutics
{{cite web |title=Alia Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/alia-therapeutics |website=VCBacked |access-date=September 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated